A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer

Lung Cancer

Volumn 70, Issue 3, 2010, Pages 340-346

  Treat, Joseph ^a   Edelman, Martin J ^b   Belani, Chandra P ^c   Socinski, Mark A ^d   Monberg, Matthew J ^a   Chen, Ruqin ^a   Obasaju, Coleman K ^a  

^a Lilly USA   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^c PENN STATE CANCER INSTITUTE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Carboplatin; Gemcitabine; Histology; Non platinum doublets; NSCLC; Paclitaxel; Phase III; Squamous

Indexed keywords

CARBOPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 77958041352     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.02.011     Document Type: Article

References (41)

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995, 311:899-909.
2. Grilli R., Oxman A.D., Julian J.A. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?. J Clin Oncol 1993, 11:1866-1872.
3. Marino P., Pampallona S., Preatoni A., Cantoni A., Invernizzi F. Chemotherapy vs. supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994, 106:861-865.
4. Souquet P.J., Chauvin F., Boissel J.P., Cellerino R., Cormier Y., Ganz P.A., et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993, 342:19-21.
5. Rajeswaran A., Trojan A., Burnand B., Giannelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 2007.
6. D'Addario G., Pintilie M., Leighl N.B., Feld R., Cerny T., Shepherd F.A. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005, 23:2926-2936.
7. Kosmidis P., Mylonakis N., Nicolaides C., Kalophonos C., Samantas E., Boukovinas J., et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002, 20:3578-3585.
8. Kosmidis P.A., Kalofonos H.P., Christodoulou C., Syrigos K., Makatsoris T., Skarlos D., et al. Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 2008, 19:115-122.
9. Scagliotti G.V., De Marinis F., Rinaldi M., Crino L., Gridelli C., Ricci S., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20:4285-4291.
10. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
11. Hirsch F.R., Spreafico A., Novello S., Wood M.D., Simms L., Papotti M., et al. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 2008, 3:1468-1481.
12. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22:330-353.
13. Stanley K.E. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980, 65:25-32.
14. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
15. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14:253-263.
16. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
17. Ohe Y., Ichinose Y., Nakagawa K., Tamura T., Kubota K., Yamamoto N., et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008, 14:4206-4212.
18. Zinner R.G., Novello S., Peng G., Herbst R., Obasaju C., Scagliotti G. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials. Clin Lung Cancer 2010, 11(2):126-131.
19. Bonomi P., Kim K., Fairclough D., Cella D., Kugler J., Rowinsky E., et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000, 18:623-631.
20. Bhatia S., Hanna N., Ansari R., Pletcher W., Einhorn L., Ng E., et al. A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. Lung Cancer 2002, 38:73-77.
21. Einhorn L., Raghavan D., Kindler H., Gordaon M., Fox S., Meyers T., et al. A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors. Proc Am Soc Clin Oncol 1998, 17:796. [abstract].
22. Giaccone G., Smit E.F., Laan D., Splinter T., van Meerbeeck J.P., Postmus P., et al. Phase I/II study of paclitaxel and gemcitabine in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1998, 17:1869. (abstract).
23. Rothenberg M.L., Sharma A., Weiss G.R., Villalona-Calero M.A., Eckardt J.R., Aylesworth C., et al. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol 1998, 9:733-738.
24. Domine M., Casado V., Esteves L Phase II study of carboplatin (C)-gemcitabine (G) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000, 19:2107. [abstract].
25. Mott F.E., Cable C.T., Sharma N. Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer. Clin Lung Cancer 2003, 5:174-176.
26. Obasaju C.K., Ye Z., Bloss L.P., Monberg M.J., Curiel R.E. Gemcitabine/carboplatin in patients with metastatic non-small-cell lung cancer: phase II study of 28-day and 21-day schedules. Clin Lung Cancer 2005, 7:202-207.
27. Treat J.A., Gonin R., Socinski M.A., Edelman M.J., Catalano R.B., Marinucci D.M., et al. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol 2010, 21(3):540-547.
28. Calvert A.H., Newell D.R., Gumbrell L.A., O'Reilly S., Burnell M., Boxall F.E., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7:1748-1756.
29. Fleming I., Cooper J., Henson D. AJCC cancer staging manual 1997, Lippincott-Raven, Philadelphia. 5th ed.
30. Kaplan E., Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc 1958, 53:457-481.
31. Therasse P., Arbuck S., Eisenhauer E. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
32. NCI Common Toxicity Criteria Version 2.0. Cancer Therapy Evaluation Program; 1999.
33. O'Brien P.C., Fleming T.R. A multiple testing procedure for clinical trials. Biometrics 1979, 35:549-556.
34. Cox D., Snell E. Analysis of Binary Data 1989, Chapman & Hall, London. 2nd ed.
35. Scagliotti G.V., De Marinis F., Rinaldi M., Crinò L., Gridelli C., Ricci S., et al. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. J Thorac Oncol 2009, 4(12):1568-1571.
36. Clements K, Peltz G, Faries D, et al: Does type of tumor histology impact survival among elderly patients with stage IIIB/IV non-small cell lung cancer treated with first-line doublet chemotherapy? J Thorac Oncol; in press.
37. Fidias P.M., Dakhil S.R., Lyss A.P., Loesch D.M., Waterhouse D.M., Bromund J.L., et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:591-598.
38. Pimentel F, Von Pawel J, Martin R, Novello S, Douillard J, O'Brien M., et al. Resource utilization by non-small cell lung cancer histology: results from the randomized, phase III trial of pemetrexed/cisplatin versus gemcitabine/cisplatin. J Clin Oncol, 2008 ASCO annual meeting proceedings: part I. 26 (Suppl. 15) 8097(abstract); 2008.
39. Bepler G., Kusmartseva I., Sharma S., Gautam A., Cantor A., Sharma A., et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006, 24:4731-4737.
40. Reynolds C., Obasaju C., Schell M.J., Li X., Zheng Z., Boulware D., et al. Randomized phase III trial of gemciatbine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small cell lung cancer. J Clin Oncol 2009, 27:5808-5815.
41. Zheng Z., Chen T., Li X., Haura E., Sharma A., Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007, 356:800-808.